A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology-Reference-Cited by-同舟云学术

A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

Published:2012-06 Issue:6 Volume:52 Page:798-808
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Hu Xiao,Miller Larisa,Richman Sandra,Hitchman Stacy,Glick Gabrielle,Liu Shifang,Zhu Ying,Crossman Mary,Nestorov Ivan,Gronke Robert S.,Baker Darren P.,Rogge Mark,Subramanyam Meena,Davar Gudarz

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference24 articles.

1. Interferon beta-1a is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter randomized double-blind placebo-controlled trial;The IFNB Multiple Sclerosis Study Group.;Neurology,1993

2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG);Jacobs;Ann Neurol,1996

3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis;PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group.;Lancet,1998

4. Switching algorithms: from one immunomodulatory agent to another;Coyle;J Neurol,2008

5. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject;Mohr;Ann Behav Med,2001

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY);Multiple Sclerosis and Related Disorders;2024-10

2. Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-09-10

3. Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation;Journal of Biological Engineering;2024-04-04

4. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

5. Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond;Seminars in Immunology;2024-03